Category - Developments

Developments

First participant dosed in Monte Rosa’s Phase 1 study of MRT-6160 for autoimmune disease

Monte Rosa Therapeutics (NASDAQ:GLUE) announced that the first participant has been dosed in its Phase 1 healthy volunteer study evaluating MRT-6160, a VAV1-directed MGB being developed for systemic and neurological...

August 19, 2024

Developments

Optimi Health announces export of first MDMA capsules for PTSD to Australia

Optimi Health (CSE:OPTI; OTCQX:OPTHF; FSE:8BN) reports completion of its inaugural export of GMP-validated, 3,4-methylenedioxymethamphetamine (MDMA) capsules to Australia for the treatment of patients with post...

August 16, 2024

Developments

Perimeter reports progress on several fronts

Perimeter Medical Imaging AI (TSX:PINK; OTC:PYNKF; FSE:4PC) highlighted several positive developments and achievements in its Q2 report and conference call yesterday. Perimeter is a medical technology company working to...

August 15, 2024

Developments

Zomedica partners with SIRE to expand sales into Central America

Zomedica (NYSEA:ZOM) announced the expansion of its sales reach into Costa Rica through a partnership with SIRE Veterinario, which will be the exclusive distributor of Zomedica products in that country. “Our...

August 14, 2024

Developments

FDA accepts scPharmaceuticals sNDA to expand heart failure drug indication

scPharmaceuticals (NASDAQ:SCPH) has announced FDA approval of its supplemental NDA (sNDA) for FUROSCIX, expanding its indication to New York Heart Association (NYHA) Class IV chronic heart failure patients. Previously...

August 12, 2024

Developments

NIH awards grant to Marker Therapeutics through SBIR program

Marker Therapeutics (NASDAQ:MRKR) has announced that it has been awarded a $2 million grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program to support the clinical...

August 12, 2024

Developments

Awakn screens first patient in Phase 3 trial of treatment for AUD

Awakn Life Sciences (CSE:AWKN; OTCQB:AWKNF; FSE:954) has announced that the first patient has been screened in its landmark MORE-KARE Phase 3 trial of AWKN-001, an investigational, novel medication-assisted treatment...

August 9, 2024

Developments

Veru meets full enrollment target in Phase 2b study of Enobosarm for Obesity

Veru (NASDAQ:VERU) announced that it has reached its targeted full enrollment of 150 patients for its Phase 2b QUALITY clinical trial of enobosarm, in combination with semaglutide, aimed at muscle preservation for high...

August 8, 2024

Developments

Rockwell launches ergonomic hemodialysis packaging solution for home patients and acute facilities

Rockwell Medical (NASDAQ:RMTI) announced the launch of a convenience pack including pre-mixed containers of the company’s hemodialysis concentrate products, offering in-home dialysis patients and acute dialysis...

August 8, 2024

Developments

89bio names Francis Sarena as COO

89Bio (NASDAQ:ETNB) announced the appointment of Francis Sarena as chief operating officer, effective August 5, 2024. Mr. Sarena brings 25 years of biotech industry experience to his new role at 89bio. Prior to joining...

August 7, 2024

Category - Developments

Subscribe